Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
toremifene
Orion Corporation
L02BA02
toremifene
Endocrine therapy
Breast Neoplasms
First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours.
Revision: 25
Authorised
1996-02-14
17 B. PACKAGE LEAFLET DNO 090017ff8067d83a IN-PROGRESS / 27.3 Confidential 17 / 23 DNO 090017ff8067d83a REVIEWED / 27.3 Confidential 17 / 23 DNO 090017ff8067d83a APPROVED / 28.0 Confidential 17 / 23 18 PACKAGE LEAFLET: INFORMATION FOR THE USER FARESTON 60 MG TABLETS toremifene READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Fareston is and what it is used for 2. What you need to know before you take Fareston 3. How to take Fareston 4. Possible side effects 5. How to store Fareston 6. Contents of the pack and other information 1. WHAT FARESTON IS AND WHAT IT IS USED FOR Fareston contains the active substance toremifene, an anti-estrogen. Fareston is used for the treatment of a certain type of breast tumour in women who have had their menopause. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE FARESTON DO NOT TAKE FARESTON - if you are allergic to toremifene or any of the other ingredients of this medicine (listed in section 6). - if you have a thickening of the womb lining - if you have severe liver problems - if you were born with or have had any condition which causes certain abnormal changes in the electrical recording of the heart (electrocardiogram or ECG) - if you have a salt imbalance in the blood, especially low concentrations of potassium in the blood (hypokalaemia) which are currently not corrected by treatment - if you have a very slow heart rate (bradycardia) - if you have a heart failure - if you have a history of abnormal heart rhythms (arrhythmias) - if you are taking other medicines that m Aqra d-dokument sħiħ
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS DNO 090017ff8067d83a IN-PROGRESS / 27.3 Confidential 1 / 23 DNO 090017ff8067d83a REVIEWED / 27.3 Confidential 1 / 23 DNO 090017ff8067d83a APPROVED / 28.0 Confidential 1 / 23 2 1. NAME OF THE MEDICINAL PRODUCT Fareston 60 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 60 mg toremifene (as citrate). Excipient with known effect One tablet contains 28.5 mg of lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. White, round, flat, bevelled edge tablet with TO 60 on one side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is 60 mg daily. _Renal impairment_ No dose adjustment is needed in patients with renal insufficiency. _Hepatic impairment_ Toremifene should be used cautiously in patients with liver impairment (see section 5.2). _Pediatric population_ There is no relevant use of Fareston in the paediatric population. Method of administration Toremifene is administered orally. Toremifene can be taken with or without food. 4.3 CONTRAINDICATIONS - Pre-existing endometrial hyperplasia and severe hepatic failure are contra-indications in long- term use of toremifene. - Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. - Both in preclinical investigations and in humans, changes in cardiac electrophysiology have been observed following exposure to toremifene, in the form of QT prolongation. For reasons of drug safety, toremifene is therefore contraindicated in patients with: - Congenital or documented acquired QT prolongation DNO 090017ff8067d83a IN-PROGRESS / 27.3 Confidential 2 / 23 DNO 090017ff8067d83a REVIEWED / 27.3 Confidential 2 / 23 DNO 090017ff8067d83a APPROVED / 28.0 Confidential 2 / 23 3 Aqra d-dokument sħiħ